Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. - Wikidata - awgldk - TriplyDB

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.

http://www.wikidata.org/entity/Q37319470

about

DNA damage, tumor mutational load and their impact on immune responses against cancer Neoantigen-based cancer immunotherapy Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer Meningioma Genomics: Diagnostic, Prognostic, and Therapeutic Applications.Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer Genomic alterations and molecular subtypes of gastric cancers in Asians Immunotherapy for lung cancer Cancer immunotherapy: the beginning of the end of cancer?Advances in immunotherapy for melanoma Novel technologies and emerging biomarkers for personalized cancer immunotherapy Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model.Technological considerations for genome-guided diagnosis and management of cancer High-content molecular profiling of T-cell therapy in oncology Recent advances in understanding antitumor immunity Immunotherapy in human colorectal cancer: Challenges and prospective Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective Biomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and others The genetics of uveal melanoma: current insights Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation The role of immune checkpoint inhibition in the treatment of ovarian cancer CANCER. The odds of immunotherapy success Identification of Glycopeptides as Posttranslationally Modified Neoantigens in Leukemia.Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial Unsupervised HLA Peptidome Deconvolution Improves Ligand Prediction Accuracy and Predicts Cooperative Effects in Peptide-HLA Interactions.T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients.The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine.Prediction and prioritization of neoantigens: integration of RNA sequencing data with whole-exome sequencing.A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D.Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden Immunotherapy in genitourinary malignancies.Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.Genomic analysis and clinical management of adolescent cutaneous melanoma.Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions.A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapy The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome Driving CAR T-cells forward Translating RNA sequencing into clinical diagnostics: opportunities and challenges.Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.

P2860

Q26738685-62E61987-89FA-4B3C-B92B-4D77F9EFB214 Q26738693-04EDED52-F4F5-4745-BF9F-8EFA40002098 Q26740288-9E45D609-F53F-4007-850F-BCE8AB9421C5 Q26741529-241DFD30-1089-4E98-A00A-49DA6D37590B Q26745590-5BEC9C8E-A5C5-4F17-BD8B-1BDC35E9EAAF Q26751062-D0F85313-6113-4C15-9704-B3AB2CAA925C Q26751254-BF838CDB-CF7F-4DD1-9E08-BEC7E963F2CB Q26752277-B270DD77-B035-42AA-BD42-AD989A968BC2 Q26768558-DA6F2F19-A1EF-44F0-8B7A-E9FFC45F3723 Q26770780-C68A26F4-2758-4C29-8907-1512346A9F36 Q27691330-532E29E2-F196-48E8-AF11-6BA9874B1E8A Q28066706-C2DBB4BD-D9FB-479E-A69C-A52DA2869E4C Q28066792-63CED280-846A-45D6-9FE4-E6618D03B0E8 Q28067217-50E0DAF3-C551-4FD4-B600-4333E98EB59D Q28068788-C05B6CED-11BB-4E10-9A01-F96FF8413556 Q28070038-8DB8E5DC-BC6B-4223-8A4E-717881935241 Q28072468-489F082C-8D82-4182-9525-BBD9F2885218 Q28073150-2115B4AF-C280-4816-9BA8-E51422997D5C Q28075719-AE0B9693-3201-4B4A-A96A-7149B1FAED14 Q28077924-E6396C6C-2E79-435E-8371-E4B09DDC91CB Q28268271-96620ABD-E784-4C6F-B493-341815B25D4A Q30252929-3E7FE6C2-9EC0-45DC-9649-585EB3354E91 Q30275266-2451F41E-A06F-436E-A945-F0A5B7F7B059 Q30277192-F00F9443-0524-4ACC-91D2-30E4304979C9 Q30391717-D5243711-421E-43D6-8B68-8C73BFBD785E Q30832820-9773FECB-C5D2-42F5-90C1-E83E092D3341 Q30846001-702D6A4B-3AE6-4DE0-973F-0E3EB241B1FE Q31117752-175077D5-3146-4EE9-922F-98A96BEFA15C Q31148562-FAA68EC7-0D19-4D3D-A001-83706198B263 Q33438485-F9E12A96-C807-40D4-ADFD-BAA18C4FD240 Q33576170-3CFEF390-E14A-4A71-88DC-96AD4A0E6EEF Q33593800-3579D37E-A4DD-4E64-A5BF-0B5615321E9F Q33608156-61F119B7-B3D1-4FEB-8EC2-36897660D7A5 Q33701435-138BA0B3-D7BD-4211-868C-CDC765DECCF9 Q33766695-402A97B3-581E-45B7-AF2D-0217F35C5BA6 Q33769203-8FF34FD1-1C28-4E53-8CF7-73FA74D3119D Q33913152-A9B407C9-564E-4BB4-A12F-E04A8B65853A Q34046505-3D7E898A-7BC5-46F4-BB7C-D0223897B730 Q34519034-4CD7CA37-BC3A-4E66-8DC3-3C176B838151 Q34522172-9FE198E4-8C46-4501-A2A1-2E1122A47C55

P2860

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.

http://www.wikidata.org/entity/Q37319470

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 September 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.

@en

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.

@nl

type

label

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.

@en

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.

@nl

altLabel

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

@en

prefLabel

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.

@en

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.

@nl

P1433

Q37319470-1B1D48BE-785C-420B-9384-71D45FA91DA7

P1476

Q37319470-437782D2-64A5-4EC5-8957-8328C01CED02

P2093

Q37319470-0BC4572F-D04A-4D6E-8EEC-4F86CD47DE94

Q37319470-26B6CEA8-2E47-42FB-9451-2F1A4D810D4D

Q37319470-3D7E2D9E-2E2E-4C24-82C5-EEC3055A5D7E

Q37319470-422A4649-3514-4DD7-BFB0-6E774F91B64C

Q37319470-51BD6FFD-CA52-4F9C-B37A-F1B169CE19B3

Q37319470-53FC86DB-DEF2-4E81-A711-AADC8449EEC7

Q37319470-54F9DBBE-4360-4DE4-B2BE-50E678E6DBAB

Q37319470-935E372C-AFC9-408E-9D95-6DF0ACC935C3

Q37319470-9431B6F2-E827-43D9-88DF-14C2E0EF2DE7

Q37319470-9AB92108-623A-4B83-BF52-1BC9E18A9E6D

P2860

Q37319470-01F14F64-2233-4466-BC1B-81A50855B3D8

Q37319470-1043DB43-0D62-45C4-A51A-612585DB20D3

Q37319470-23BC9D29-808F-4DB8-9F79-AF092D8C3CE0

Q37319470-35465D5C-5864-4B67-B1D8-1CC837596675

Q37319470-3D454200-EC2F-4E6B-8776-E47714E8A815

Q37319470-4299E746-5918-40D6-8C03-3593E73E477A

Q37319470-42B6C8C4-C30D-43EB-9F30-035983287DD3

Q37319470-444AEA62-5E00-461A-A1E8-DA258185CAA7

Q37319470-49B4A9A1-FC02-427B-91AE-3A55261B0722

Q37319470-49F3BBE0-B333-46C8-B41C-B5EFE7E56AAD

P304

Q37319470-AEEAADB9-B4FA-43D0-AB25-37BB012E4A51

P31

Q37319470-7B5413B8-D9D2-4885-ADF9-D7CBE9CEB5DF

P356

Q37319470-61BD6C5B-0883-481B-BA22-D805AF964889

P407

Q37319470-35FF511A-BD07-47AD-9775-D0D7B211C712

P433

Q37319470-34AB57D6-8A05-4221-81C7-F4632ED5AE94

P478

Q37319470-2EDCDD1D-7A50-4038-958D-C63BFA278F70

P50

Q37319470-3D876F9B-1654-4E3F-891B-C92F0EBE22DA

Q37319470-A8789AEE-B7C1-4009-81A9-3522C7372BE1

Q37319470-C2BE48B6-180C-48CA-9BB9-12EBCB00F435

Q37319470-E77647D1-4BD1-4428-B95B-B86CC7136E4D

P577

Q37319470-412DAB45-33B1-4DA0-BAA6-F1B77F7AF70B

P5875

Q37319470-1FB619C1-BF77-44AC-A677-20D930434299

P698

Q37319470-272D4780-890A-4056-876F-E2A88D7D8756

P932

Q37319470-A6B07014-75B1-42E4-8881-D1F6F80C00F7

P356

SCIENCE.AAD0095

P1433

P1476

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.

@en

P2093

Bastian Schilling

http://www.w3.org/2001/XMLSchema#string

Benjamin Weide

http://www.w3.org/2001/XMLSchema#string

Carmen Loquai

http://www.w3.org/2001/XMLSchema#string

Catherine J Wu

http://www.w3.org/2001/XMLSchema#string

Christian Blank

http://www.w3.org/2001/XMLSchema#string

Diana Miao

http://www.w3.org/2001/XMLSchema#string

Eliezer M Van Allen

http://www.w3.org/2001/XMLSchema#string

Jessica C Hassel

http://www.w3.org/2001/XMLSchema#string

Jochen Utikal

http://www.w3.org/2001/XMLSchema#string

Katharina C Kaehler

http://www.w3.org/2001/XMLSchema#string

P2860

A landscape of driver mutations in melanoma

Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

The future of immune checkpoint therapy

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Integrative genomics viewer

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

P304

207-211

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCIENCE.AAD0095

http://www.w3.org/2001/XMLSchema#string

P407

P433

6257

http://www.w3.org/2001/XMLSchema#string

P478

350

http://www.w3.org/2001/XMLSchema#string

P50

Dirk Schadendorf

Levi A Garraway

P577

2015-09-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281680522

http://www.w3.org/2001/XMLSchema#string

P698

26359337

http://www.w3.org/2001/XMLSchema#string

P932

5054517

http://www.w3.org/2001/XMLSchema#string